Eisai To Start Rufinamide Phase III For Lennox-Gastaut Syndrome In Japan
This article was originally published in PharmAsia News
Executive Summary
Eisai prepares to commence a Japanese Phase III trial for Banzel (rufinamide) to treat Lennox-Gastaut Syndrome in the first half of FY 2010